Line 30: |
Line 30: |
| |} | | |} |
| ==Definition / Description of Disease== | | ==Definition / Description of Disease== |
− | T-prolymphocytic leukemia (T-PLL) is a clonal proliferation of small to medium-sized prolymphocytes with a mature post thymic T-cell phenotype characterized by the juxtaposition of TCL1A or MTCP1 to a TR locus, most often the TRA/TRD locus. | + | T-prolymphocytic leukemia (T-PLL) is an aggressive form of T-cell leukemia marked by the proliferation of small to medium-sized prolymphocytes exhibiting a mature post-thymic T-cell phenotype. This condition is characterized by the juxtaposition of TCL1A or MTCP1 genes to a TR locus, typically the TRA/TRD locus. |
| ==Synonyms / Terminology== | | ==Synonyms / Terminology== |
| Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span> | | Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span> |
| ==Epidemiology / Prevalence== | | ==Epidemiology / Prevalence== |
− | T-PLL is rare, accounting for approximately 2% of cases of mature lymphoid leukemias in adults aged over 30 years. It predominantly affects the elderly (median age: 65 years, range: 30–94 years) with a slight male predominance (M:F ratio: 1.33:1). | + | T-PLL is a rare disorder, comprising about 2% of all mature lymphoid leukemia cases in adults. It primarily occurs in the elderly, with a median age of 65 years (ranging from 30 to 94 years), and shows a slight male predominance with a male to female ratio of 1.33:1. |
| ==Clinical Features== | | ==Clinical Features== |
| Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span> | | Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span> |
Line 52: |
Line 52: |
| | | |
| Marked lymphocytosis > 100 × 10^9/L (75% of cases) | | Marked lymphocytosis > 100 × 10^9/L (75% of cases) |
− |
| |
− | <span class="blue-text">EXAMPLE:</span> Lymphocytosis (low level)
| |
| |} | | |} |
| ==Sites of Involvement== | | ==Sites of Involvement== |
Line 67: |
Line 65: |
| |Positive (universal)||CD2, CD3 (may be weak), CD5, CD7 | | |Positive (universal)||CD2, CD3 (may be weak), CD5, CD7 |
| |- | | |- |
− | |Positive (subset)||CD4 (in some cases CD4+/CD8+ or CD4-/CD8+), CD52 | + | |Positive (subset)||CD4 (in some cases CD4+/CD8+ or CD4-/CD8+), CD52 |
| |- | | |- |
| |Negative (universal)||TdT, CD1a | | |Negative (universal)||TdT, CD1a |
Line 83: |
Line 81: |
| !Notes | | !Notes |
| |- | | |- |
− | |t(14;14)(q11;q32)||TCL1A/TRD||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) | + | |t(14;14)(q11;q32) |
| + | |TCL1A/TRD||<span class="blue-text">EXAMPLE:</span> der(22)||<span class="blue-text">EXAMPLE:</span> 20% (COSMIC) |
| <span class="blue-text">EXAMPLE:</span> 30% (add reference) | | <span class="blue-text">EXAMPLE:</span> 30% (add reference) |
| |Yes | | |Yes |
Line 94: |
Line 93: |
| |MTCP1/TRD | | |MTCP1/TRD |
| | | | | |
− | |Low | + | |Low (5%) |
| | | | | |
| | | | | |
Line 110: |
Line 109: |
| !Notes | | !Notes |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> | + | |8 |
− | 8 | + | |Gain |
− | |<span class="blue-text">EXAMPLE:</span> Gain | + | |idic(8)(p11.2) |
− | |<span class="blue-text">EXAMPLE:</span> | + | |
− | <br /> | + | t(8;8)(p11.2;q12) |
− | |<span class="blue-text">EXAMPLE:</span> | + | |
− | chr8
| + | trisomy 8q<br /> |
− | |<span class="blue-text">EXAMPLE:</span> No | + | |chr8 |
− | |<span class="blue-text">EXAMPLE:</span> No | + | |No |
− | |<span class="blue-text">EXAMPLE:</span> No | + | |No |
− | |<span class="blue-text">EXAMPLE:</span> | + | |No |
− | Common recurrent secondary finding for t(8;21) (add reference).
| + | |Common recurrent secondary finding (70-80% of cases).<ref>{{Cite journal|last=Matutes|first=E.|last2=Brito-Babapulle|first2=V.|last3=Swansbury|first3=J.|last4=Ellis|first4=J.|last5=Morilla|first5=R.|last6=Dearden|first6=C.|last7=Sempere|first7=A.|last8=Catovsky|first8=D.|date=1991-12-15|title=Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/1742486|journal=Blood|volume=78|issue=12|pages=3269–3274|issn=0006-4971|pmid=1742486}}</ref> |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| |} | | |} |
| ==Characteristic Chromosomal Patterns== | | ==Characteristic Chromosomal Patterns== |
Line 133: |
Line 141: |
| !Notes | | !Notes |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> | + | |inv(14)(q11q32) |
− | Co-deletion of 1p and 18q
| |
| |<span class="blue-text">EXAMPLE:</span> Yes | | |<span class="blue-text">EXAMPLE:</span> Yes |
| |<span class="blue-text">EXAMPLE:</span> No | | |<span class="blue-text">EXAMPLE:</span> No |
Line 166: |
Line 173: |
| |<span class="blue-text">EXAMPLE:</span> No | | |<span class="blue-text">EXAMPLE:</span> No |
| |<span class="blue-text">EXAMPLE:</span> Excludes hairy cell leukemia (HCL) (add reference). | | |<span class="blue-text">EXAMPLE:</span> Excludes hairy cell leukemia (HCL) (add reference). |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | |TCL1A |
| + | |Oncogene |
| + | | |
| + | |ATM mutations |
| + | |None specified |
| + | |Yes |
| + | |Yes |
| + | | |
| + | | |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | |- |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| + | | |
| |}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | | |}Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. |
| ==Epigenomic Alterations== | | ==Epigenomic Alterations== |
Line 179: |
Line 226: |
| |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation | | |<span class="blue-text">EXAMPLE:</span> Increased cell growth and proliferation |
| |- | | |- |
− | |<span class="blue-text">EXAMPLE:</span> ''CDKN2A''; Inactivating mutations | + | |TCL1A |
− | |<span class="blue-text">EXAMPLE:</span> Cell cycle regulation | + | |T-cell signaling |
− | |<span class="blue-text">EXAMPLE:</span> Unregulated cell division | + | |Increased cell survival and proliferation |
| |- | | |- |
| |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations | | |<span class="blue-text">EXAMPLE:</span> ''KMT2C'' and ''ARID1A''; Inactivating mutations |
Line 188: |
Line 235: |
| |} | | |} |
| ==Genetic Diagnostic Testing Methods== | | ==Genetic Diagnostic Testing Methods== |
− | Put your text here
| + | The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the TCL1 gene at the TRB or TRG loci. |
| ==Familial Forms== | | ==Familial Forms== |
− | Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>
| + | A subset of cases may develop in the context of ataxia-telangiectasia (AT), which is characterized by germline mutations in the ATM gene. Penetrance of the tumor phenotype is about 10% to 15% by early adulthood.<ref>{{Cite journal|last=Taylor|first=A. M.|last2=Metcalfe|first2=J. A.|last3=Thick|first3=J.|last4=Mak|first4=Y. F.|date=1996-01-15|title=Leukemia and lymphoma in ataxia telangiectasia|url=https://pubmed.ncbi.nlm.nih.gov/8555463|journal=Blood|volume=87|issue=2|pages=423–438|issn=0006-4971|pmid=8555463}}</ref> It represents nearly 3% of all malignancies in patients with ataxia-telangiectasia.<ref>{{Cite journal|last=Li|first=Geling|last2=Waite|first2=Emily|last3=Wolfson|first3=Julie|date=2017-12-26|title=T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)|url=https://pubmed.ncbi.nlm.nih.gov/29296924|journal=Blood Advances|volume=1|issue=27|pages=2724–2728|doi=10.1182/bloodadvances.2017010470|issn=2473-9529|pmc=5745136|pmid=29296924}}</ref> |
| ==Additional Information== | | ==Additional Information== |
| Put your text here | | Put your text here |
Line 203: |
Line 250: |
| [[Category:DISEASE]] | | [[Category:DISEASE]] |
| [[Category:Diseases T]] | | [[Category:Diseases T]] |
| + | <references /> |